Wall Street Zen cut shares of Humana (NYSE:HUM – Free Report) from a buy rating to a hold rating in a research report sent to investors on Sunday,Wall Street Zen reports.
HUM has been the topic of several other reports. Leerink Partners upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price objective on the stock in a research report on Thursday, July 30th. Guggenheim raised their target price on shares of Humana from $269.00 to $471.00 and gave the company a “buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. lifted their target price on shares of Humana from $316.00 to $393.00 and gave the stock a “neutral” rating in a research report on Monday, August 10th. Morgan Stanley raised shares of Humana from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $249.00 to $370.00 in a report on Tuesday, August 4th. Finally, Wolfe Research reiterated an “outperform” rating and issued a $450.00 price target on shares of Humana in a research report on Monday, August 24th. Fifteen equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $408.61.
Get Our Latest Stock Report on Humana
Humana Price Performance
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to analysts’ expectations of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.Humana’s revenue was up 26.2% on a year-over-year basis. During the same period in the previous year, the firm posted $6.27 earnings per share. As a group, equities analysts forecast that Humana will post 9 earnings per share for the current fiscal year.
Humana Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, November 27th. Shareholders of record on Friday, October 30th will be paid a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, October 30th. Humana’s dividend payout ratio (DPR) is currently 33.49%.
Hedge Funds Weigh In On Humana
A number of institutional investors have recently modified their holdings of the company. Manning & Napier Advisors LLC acquired a new position in Humana in the 2nd quarter valued at $1,412,000. Sustainable Insight Capital Management LLC lifted its stake in shares of Humana by 23.7% during the 4th quarter. Sustainable Insight Capital Management LLC now owns 24,757 shares of the insurance provider’s stock worth $6,341,000 after purchasing an additional 4,740 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Humana by 10.5% during the second quarter. The Manufacturers Life Insurance Company now owns 70,185 shares of the insurance provider’s stock worth $27,879,000 after purchasing an additional 6,690 shares during the last quarter. Pzena Investment Management LLC acquired a new stake in shares of Humana during the second quarter worth $1,749,014,000. Finally, Ameritas Advisory Services LLC purchased a new stake in shares of Humana in the second quarter valued at $1,709,000. Institutional investors and hedge funds own 92.38% of the company’s stock.
About Humana
Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.
Humana’s insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.
See Also
- Five stocks we like better than Humana
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
